However, G-CSF levels in individuals with APLAID remained elevated despite the administration of biologics targeting IL-1, for example, arguing that G-CSF is not a nonspecific feature of inflammation in APLAID. The gene discussed is CSF3; the disease is autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.